SAB is developing SAB-142 as a disease-modifying immunotherapy aimed at delaying the onset and progression of T1D. The chronic burden of type 1 diabetes is multifaceted, impacting a …

Find the latest SAB Biotherapeutics, Inc. (SABS) stock quote, history, news and other vital information to help you with your stock trading and investing.

6 days ago · A detailed overview of SAB Biotherapeutics, Inc. (SABS) stock, including real-time price, chart, key statistics, news, and more.

SAB Biotherapeutics, Inc. is a biotechnology company whose primary activities include the development of a therapeutic pipeline, funded in part through equity offerings of its common …

Jul 21, 2025 · SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs), without the need for human …

Jul 21, 2025 · SAB Biotherapeutics secured $175 million in an oversubscribed private placement, with potential for an additional $284 million from warrants, extending its cash runway into mid …

2 days ago · SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune …

Dec 19, 2025 · View SAB Biotherapeutics, Inc. SABS stock quote prices, financial information, real-time forecasts, and company news from CNN.

5 days ago · SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short …

Company Profile SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders.